Demant
Market Cap
kr.51.2b
Last Updated
2020/10/21 21:11 UTC
Data Sources
Company Financials +
Executive Summary
Demant A/S, a hearing healthcare company, develops, manufactures, and sells products and equipment to enhance people’s hearing in Europe, North America, the Pacific, Asia, and internationally. More Details
Snowflake Analysis
Reasonable growth potential with mediocre balance sheet.
Similar Companies
Share Price & News
How has Demant's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: DEMANT has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
4.3%
DEMANT
-0.8%
DK Medical Equipment
-3.6%
DK Market
1 Year Return
22.4%
DEMANT
34.6%
DK Medical Equipment
30.3%
DK Market
Return vs Industry: DEMANT underperformed the Danish Medical Equipment industry which returned 33.4% over the past year.
Return vs Market: DEMANT underperformed the Danish Market which returned 32.2% over the past year.
Shareholder returns
| DEMANT | Industry | Market | |
|---|---|---|---|
| 7 Day | 4.3% | -0.8% | -3.6% |
| 30 Day | 16.7% | 4.4% | 5.0% |
| 90 Day | 9.1% | -2.8% | 5.2% |
| 1 Year | 22.4%22.4% | 36.3%34.6% | 32.8%30.3% |
| 3 Year | 19.7%19.7% | 78.7%71.4% | 51.0%39.6% |
| 5 Year | 78.7%78.7% | 152.9%132.9% | 66.2%45.5% |
Price Volatility Vs. Market
How volatile is Demant's share price compared to the market and industry in the last 5 years?
Simply Wall St News
4 days ago | Simply Wall St
Calculating The Intrinsic Value Of Demant A/S (CPH:DEMANT)2 weeks ago | Simply Wall St
Is There Now An Opportunity In Demant A/S (CPH:DEMANT)?4 weeks ago | Simply Wall St
Investors Who Bought Demant (CPH:DEMANT) Shares Five Years Ago Are Now Up 67%Valuation
Is Demant undervalued compared to its fair value and its price relative to the market?
62.98x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: DEMANT (DKK213.5) is trading above our estimate of fair value (DKK177.21)
Significantly Below Fair Value: DEMANT is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: DEMANT is good value based on its PE Ratio (63x) compared to the DK Medical Equipment industry average (63.8x).
PE vs Market: DEMANT is poor value based on its PE Ratio (63x) compared to the Danish market (16.6x).
Price to Earnings Growth Ratio
PEG Ratio: DEMANT is poor value based on its PEG Ratio (2.5x)
Price to Book Ratio
PB vs Industry: DEMANT is good value based on its PB Ratio (6.9x) compared to the DK Medical Equipment industry average (10.5x).
Next Steps
Future Growth
How is Demant forecast to perform in the next 1 to 3 years based on estimates from 20 analysts?
25.1%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: DEMANT's forecast earnings growth (25.1% per year) is above the savings rate (0.3%).
Earnings vs Market: DEMANT's earnings (25.1% per year) are forecast to grow faster than the Danish market (12% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: DEMANT's revenue (10.4% per year) is forecast to grow faster than the Danish market (6.4% per year).
High Growth Revenue: DEMANT's revenue (10.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: DEMANT's Return on Equity is forecast to be low in 3 years time (19.9%).
Next Steps
Past Performance
How has Demant performed over the past 5 years?
-0.06%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: DEMANT has high quality earnings.
Growing Profit Margin: DEMANT's current net profit margins (6%) are lower than last year (11.7%).
Past Earnings Growth Analysis
Earnings Trend: DEMANT's earnings have declined by 0.06% per year over the past 5 years.
Accelerating Growth: DEMANT's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: DEMANT had negative earnings growth (-51.7%) over the past year, making it difficult to compare to the Medical Equipment industry average (-51.7%).
Return on Equity
High ROE: DEMANT's Return on Equity (11%) is considered low.
Next Steps
Financial Health
How is Demant's financial position?
Financial Position Analysis
Short Term Liabilities: DEMANT's short term assets (DKK6.4B) do not cover its short term liabilities (DKK9.5B).
Long Term Liabilities: DEMANT's short term assets (DKK6.4B) exceed its long term liabilities (DKK5.1B).
Debt to Equity History and Analysis
Debt Level: DEMANT's debt to equity ratio (112.6%) is considered high.
Reducing Debt: DEMANT's debt to equity ratio has increased from 60% to 112.6% over the past 5 years.
Debt Coverage: DEMANT's debt is well covered by operating cash flow (21.8%).
Interest Coverage: DEMANT's interest payments on its debt are well covered by EBIT (7.1x coverage).
Balance Sheet
Next Steps
Dividend
What is Demant current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate DEMANT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate DEMANT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if DEMANT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if DEMANT's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of DEMANT's dividend in 3 years as they are not forecast to pay a notable one for the Danish market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
3.5yrs
Average management tenure
CEO
Søren Nielsen (50 yo)
3.5yrs
Tenure
kr.14,700,000
Compensation
Mr. Søren Nielsen has been the Chief Executive Officer and President of Demant A/S (formerly known as William Demant Holding A/S) since April 1, 2017 and has been its Member of Executive Board since Septem ...
CEO Compensation Analysis
Compensation vs Market: Søren's total compensation ($USD2.34M) is about average for companies of similar size in the Danish market ($USD2.29M).
Compensation vs Earnings: Søren's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Member of Executive Board | 3.5yrs | kr.14.70m | 0.0077% DKK 3.9m | |
| CFO & Member of Executive Board | 5.08yrs | kr.6.50m | 0.0050% DKK 2.6m | |
| Director of Investor Relations | 0.58yr | no data | no data | |
| Vice President of Corporate Communication & Relations | no data | no data | no data | |
| President of Oticon Medical | no data | no data | no data | |
| Investor Relations Officer | no data | no data | no data |
3.5yrs
Average Tenure
Experienced Management: DEMANT's management team is considered experienced (3.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Deputy Chairman | 3.5yrs | no data | 0.42% DKK 213.8m | |
| Independent Chairman | 3.75yrs | no data | 0.0034% DKK 1.7m | |
| Independent Director | 4.75yrs | no data | 0.0094% DKK 4.8m | |
| Director | 3.67yrs | no data | 0.00015% DKK 76.8k | |
| Independent Director | 6.75yrs | no data | 0.0013% DKK 639.6k | |
| Director | 5.75yrs | no data | 0.00056% DKK 286.5k | |
| Director | 1.75yrs | no data | 0.00021% DKK 107.5k | |
| Director | 0.58yr | no data | no data |
3.7yrs
Average Tenure
52yo
Average Age
Experienced Board: DEMANT's board of directors are considered experienced (3.7 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Demant A/S's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Demant A/S
- Ticker: DEMANT
- Exchange: CPSE
- Founded: 1904
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: kr.51.169b
- Shares outstanding: 239.67m
- Website: https://www.demant.com
Number of Employees
Location
- Demant A/S
- Kongebakken 9
- Smørum
- Capital Region of Denmark
- 2765
- Denmark
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| WILL.F | OTCPK (Pink Sheets LLC) | Yes | Share Capital | US | USD | May 1995 |
| DEMANT | CPSE (OMX Nordic Exchange Copenhagen) | Yes | Share Capital | DK | DKK | May 1995 |
| WDH1 | DB (Deutsche Boerse AG) | Yes | Share Capital | DE | EUR | May 1995 |
| 0RGT | LSE (London Stock Exchange) | Yes | Share Capital | GB | DKK | May 1995 |
| DEMANC | BATS-CHIXE (BATS 'Chi-X Europe') | Yes | Share Capital | GB | DKK | May 1995 |
| DEMA | WBAG (Wiener Boerse AG) | Yes | Share Capital | AT | EUR | May 1995 |
| WILY.Y | OTCPK (Pink Sheets LLC) | UNSPONSORED ADS | US | USD | Nov 2008 |
Biography
Demant A/S, a hearing healthcare company, develops, manufactures, and sells products and equipment to enhance people’s hearing in Europe, North America, the Pacific, Asia, and internationally. Its products ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/10/21 21:11 |
| End of Day Share Price | 2020/10/21 00:00 |
| Earnings | 2020/06/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.